4565 Sosei Group Corporation

Sosei Heptares to host R&D Day highlighting its innovative R&D and translational medicine approaches to drug discovery and strong pipeline momentum

Sosei Heptares to host R&D Day highlighting its innovative R&D and translational medicine approaches to drug discovery and strong pipeline momentum

TOKYO and CAMBRIDGE, United Kingdom, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) will hold an R&D Day on Thursday, 13 October 2022, at 3:30 pm JST. The meeting will be held in person in Tokyo for institutional investors, securities analysts and the press and will also be available via a live webcast. Please click  to register for the event.

  • Date: Thursday, 13 October 2022 
  • Time: 3:30 pm – 5:30 pm JST (7:30 am – 9:30 am BST) 
  • Presenters:
Chris Cargill, President and CEO
 Corporate presentation, vision, strategy and progress 
  
 Matt Barnes, Head of UK R&D
 Focusing on out-licensed and partnered programs 
  
 Rie Suzuki, Senior Director, Translational Biology
 Focused on wholly owned, in-house programs

About Sosei Heptares

We are an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology and inflammatory diseases.

We have established partnerships with some of the world’s leading pharmaceutical companies and multiple emerging technology companies, including AbbVie, AstraZeneca, Genentech (Roche), GSK, Kallyope, Neurocrine Biosciences, Novartis, Pfizer, Takeda and Verily. Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in Cambridge, UK.

“Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies.

For more information, please visit

LinkedIn: | Twitter: | YouTube:

Enquiries:

Sosei Heptares – Media and Investor Relations

Hironoshin Nomura, Chief Financial Officer

Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures

Candelle Chong, SVP Investor Relations and Corporate Strategy

Japan: +81 (0)3 5210 3399 | United Kingdom: +44 (0)1223 949390 |

MEDiSTRAVA Consulting (for International Media)

Mark Swallow, Frazer Hall, Eleanor Perkin

+44 (0)203 928 6900 |



EN
27/09/2022

Underlying

4565Sosei Group Corporation

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sosei Group Corporation

 PRESS RELEASE
Free
4565 Sosei Group Cor...

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie un...

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases Tokyo, Japan and Cambridge and London, UK, 30 September 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a second important R&D milestone under its multi-target discovery collaboration with AbbVie focused on neurological diseases, resulting in a payment of US$10 million to Nxera. Nxera and AbbVie entered this multi-target collaboration in 2022 to leverage Nxera’s NxWave™ platform to discover novel medicines targeting G prot...

September 29, 2025 1 EN
 PRESS RELEASE
Free
4565 Sosei Group Cor...

Nxera Pharma and Cancer Research UK Announce First Patient Dosed in Ph...

Nxera Pharma and Cancer Research UK Announce First Patient Dosed in Phase 2a Trial of Investigational Cancer Immunotherapy HTL0039732 HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist being investigated to treat a wide range of solid cancers in combination with other immunotherapiesCancer Research UK’s Centre for Drug Development is sponsoring and managing the ongoing Phase 1/2a trial of HTL0039732 Tokyo, Japan and Cambridge and London, UK, 17 September 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) and Cancer Research UK announce that the first...

September 16, 2025 1 EN
 PRESS RELEASE
Free
4565 Sosei Group Cor...

Nxera Pharma Operational Highlights and Consolidated Results for the S...

Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025 Tokyo, Japan and Cambridge, UK, 8 August 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quarter and first half ended 30 June 2025. The full report can be found . Chris Cargill, President and CEO of Nxera, commented: “Nxera continued to make good progress in the first half of 2025. We are seeing increasing revenues from sales of PIVLAZ® and QUVIVIQ®, our marketed products in Japan,...

August 8, 2025 1 EN
 PRESS RELEASE
Free
4565 Sosei Group Cor...

Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chroni...

Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management Pipeline led by a new proprietary oral small molecule GLP-1 agonist and six additional innovative programs targeting the GIP, Amylin and Apelin receptors, aiming to transform treatment landscapeDesigned to address emerging areas of patient need, including long-term weight management, co-morbid metabolic disorders, and muscle preservation during weight loss Tokyo, Japan and Cambridge, UK, 6 August 2025 – Nxera Pharma Co., Ltd. (“Nxera”; TSE: 4565) a technology-powered biopharmaceutical company, today ...

August 5, 2025 1 EN
 PRESS RELEASE
Free
4565 Sosei Group Cor...

Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following...

Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa’s Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals pursuant to its research collaboration with Centessa. The milestones were achieved as Centessa initiated clinical development of ORX142, its second novel orexin receptor 2 (OX2R) agonist, following the recent clearance...

July 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch